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background: Several novel oral anticoagulants (NOA) have been FDA-approved for stroke prevention in patients with non-valvular atrial fibrillation 
(AF), but clinical trials have excluded patients with valvular AF. The rate of off-label adoption of NOAs for valvular AF is unknown.
methods: Using the NCDR-PINNACLE Registry, we compared outpatient prescription rates of NOAs (dabigatran, rivaroxaban) versus warfarin for 
patients with non-valvular AF with CHADS2 score ≥ 2 and all patients with valvular AF from Jan 2011 - Dec 2012. Uptake of NOAs was assessed 
quarterly. Differences between groups for continuous variables were evaluated using Student’s T-test; categorical variables were evaluated using the 
chi-square test.
results: Our cohort consisted of 190,227 non-valvular AF and 2142 valvular AF patients from 95 practices. On average, valvular AF patients were 
younger (72.7 v 75.0 yrs, p<0.001) and had a higher rate of prior stroke\TIA (42.9% v 26.7%, p<0.001). Table 1 shows uptake of NOAs by quarter. 
Initial off label uptake of NOAs in valvular AF was slower, but by the end of 2012, off label NOA rates in patients with valvular AF were not significantly 
different compared to rates in patients with non-valvular AF (13.8% v 14.9%, p=0.39).
conclusions: Although evidence of efficacy for stroke prevention in valvular AF is lacking, off-label use of NOAs for valvular AF has been rapidly 
adopted in clinical practice. Further studies are needed to evaluate the effectiveness of NOAs for stroke prevention in valvular AF.
